Current Author Addresses: Dr. Loomba: Division of Gastroenterology, Department of Medicine, University of California at San Diego, UC 303, MC063, 9500 Gilman Drive, La Jolla, CA 92093.
Drs. Rowley and Pucino: Pharmacy Department, Clinical Center, Building 10, Room 1N-257, 10 Center Drive, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD 20892.
Dr. Wesley: Hospital Epidemiology, Clinical Center, Building 10, Room 2N-228B, 10 Center Drive, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD 20892.
Dr. Liang: Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Building 10/9B-16, MSC-1800, 10 Center Drive, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD 20892.
Dr. Hoofnagle: Liver Diseases Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Building 31/9A-27, MSC-1800, 31 Center Drive, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD 20892.
Dr. Csako: Department of Laboratory Medicine, Clinical Center, Building 10, Room 2C-407, 10 Center Drive, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892.

Appendix Table. **Methodological Characteristics of Clinical Trials Assessing the Efficacy of Preventive Lamivudine***

Study, Year (Reference)	Randomization Method Reported	Detailed Inclusion or Exclusion Criteria Reported	Allocation Concealment Reported	Adherence to Assigned Treatments Described	Withdrawals among Lamivudine Recipients vs. Control Agent Recipients, *n*
Randomized, controlled trials†					
Lau et al., 2003 (8)	Yes	Yes	No	Yes	0 vs. 0
Jang et al., 2006 (21)	Yes	Yes	No	Yes	2 vs. 1‡
Prospective cohort studies with control groups†					
Jia and Lin, 2004 (20)	NA	No	No	No	NR
Idilman et al., 2004 (24)	NA	Yes	No	Yes	0 vs. 0
Shibolet et al., 2002 (25)	NA	Yes	No	Yes	0 vs. 0
Prospective cohort studies with historical control groups†					
Dai et al., 2004 (22)	NA	Yes	No	Yes	0 vs. 0
Yeo et al., 2004 (15)	NA	Yes	No	Yes	2 vs. 3§
Yeo et al., 2004 (26)	NA	Yes	No	Yes	0 vs. 0
Yeo et al., 2005 (13)	NA	Yes	No	Yes	0 vs. 0
Hsu et al., 2006 (23)	NR	No	NR	No	NR
Retrospective cohort studies‖					
Lim et al., 2002 (17)	NA	Yes	No	Yes	0 vs.0
Leaw et al., 2004 (19)	NA	Yes	No	Yes	0 vs. 0
Nagamatsu et al., 2004 (16)	NA	Yes	No	Yes	0 vs. 0
Retrospective cohort studies†					
Lee et al., 2003 (18)	NA	Yes	No	Yes	0 vs. 0

* NA = not applicable; NR = not reported.
† Preventive lamivudine vs. deferred lamivudine.
‡ Reasons for noncompletion were vascular insufficiency (1 lamivudine recipient) and unknown (1 lamivudine recipient and 1 control agent recipient).
§ Reasons for noncompletion were hyperbilirubinemia (1 lamivudine recipient and 2 control agent recipients), use of an oral cytotoxic agent (1 control agent recipient), and administration of lamivudine after initiation of chemotherapy (1 lamivudine recipient).
‖ Preventive lamivudine vs. no lamivudine.